BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23866964)

  • 1. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
    Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
    Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.
    Ji MM; Wang L; Zhan Q; Xue W; Zhao Y; Zhao X; Xu PP; Shen Y; Liu H; Janin A; Cheng S; Zhao WL
    Autophagy; 2015; 11(12):2160-71. PubMed ID: 26735433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
    Zheng Z; Zhao Y; Dong LH; Wang L; Cheng S; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1441-7. PubMed ID: 24370026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
    Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
    Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
    Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
    BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid attenuates sepsis-induced myocardial dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway.
    Shi X; Liu Y; Zhang D; Xiao D
    Life Sci; 2019 Sep; 232():116613. PubMed ID: 31265853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
    Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
    Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
    Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
    Ferreira AC; de-Freitas-Junior JC; Morgado-Díaz JA; Ridley AJ; Klumb CE
    J Leukoc Biol; 2016 Apr; 99(4):569-78. PubMed ID: 26561567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo.
    Liu W; Huang S; Chen Z; Wang H; Wu H; Zhang D
    Pathol Res Pract; 2014 Nov; 210(11):764-9. PubMed ID: 24767255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
    Ni F; Huang X; Chen Z; Qian W; Tong X
    Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
    Liu D; Xing J; Trink B; Xing M
    Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
    Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
    Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
    PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
    Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
    J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.